First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas

Cancer

Volumn 117, Issue 2, 2011, Pages 268-275

  Strosberg, Jonathan R ^a   Fine, Robert L ^b   Choi, Junsung ^a   Nasir, Aejaz ^a   Coppola, Domenico ^a   Chen, Dung Tsa ^a   Helm, James ^a   Kvols, Larry ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

carcinomas; chemotherapy; islet cell tumors; Pancreatic endocrine tumors; pancreatic neuroendocrine tumors

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; CAPECITABINE; ONDANSETRON; STREPTOZOCIN; TEMOZOLOMIDE;

ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BEDTIME DOSAGE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAND FOOT SYNDROME; HERPES LABIALIS; HERPES ZOSTER; HUMAN; HUMAN TISSUE; LEUKOPENIA; MALE; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS ISLET CELL CARCINOMA; PANCREATOGRAPHY; PANCYTOPENIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN TOXICITY; SURVIVAL RATE; SURVIVAL TIME; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VAGINA BLEEDING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, ISLET CELL; DACARBAZINE; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 78650993549     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25425     Document Type: Article

References (30)

1. Oberg K, Eriksson B., Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol. 2005; 19: 753-781.
2. Halfdanarson TR, Rubin J, Farnell MB, Grant CS, Petersen GM., Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors. Endocr Relat Cancer. 2008; 15: 409-427.
3. Strosberg J, Gardner N, Kvols L., Survival and prognostic factor analysis in patients with metastatic pancreatic endocrine carcinomas. Pancreas. 2009; 38: 255-258.
4. Strosberg J, Nasir A, Coppola D, Wick M, Kvols L., Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors. Hum Pathol. 2009; 40: 1262-1268.
5. Moertel CG, Kvols LK, O'Connell MJ, Rubin J., Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991; 68: 227-232.
6. Kulke MH, Wu B, Ryan DP, et al. A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors. Dig Dis Sci. 2006; 51: 1033-1038.
7. Hill JS, McPhee JT, McDade TP, et al. Pancreatic neuroendocrine tumors: the impact of surgical resection on survival. Cancer. 2009; 115: 741-751.
8. Madeira I, Terris B, Voss M, et al. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut. 1998; 43: 422-427.
9. Hodul PJ, Strosberg JR, Kvols LK., Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated? Cancer Control. 2008; 15: 314-321.
10. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG., Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003; 197: 29-37.
11. Norton JA, Warren RS, Kelly MG, Zuraek MB, Jensen RT., Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery. 2003; 134: 1057-1063.;discussion 1063-1055.
12. Gupta S, Yao JC, Ahrar K, et al. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J. 2003; 9: 261-267.
13. Strosberg JR, Choi J, Cantor AB, Kvols LK., Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control. 2006; 13: 72-78.
14. Ruszniewski P, Malka D., Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumors. Digestion. 2000; 62 (suppl 1): 79-83. (Pubitemid 30665944)
15. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3] octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008; 26: 2124-2130.
16. Kulke M, Bergsland E, Ryan D., A Phase 2 Study to Evaluate the Safety and Efficacy of SU11248 in Patients with Unresectable Neuroendocrine Tumors. Proceedings of ASCO. 2003; 22: A958.
17. Yao JC, Phan AT, Chang DZ, et al. Phase II study of RAD001 (everolimus) and depot octreotide (Sandostatin LAR) in patients with advanced low grade neuroendocrine carcinoma (LGNET). Journal of Clinical Oncology. 2006; 24 (18S): 4042.
18. Kvols LK, Buck M., Chemotherapy of endocrine malignancies: a review. Semin Oncol. 1987; 14: 343-353.
19. Murray-Lyon IM, Eddleston AL, Williams R, et al. Treatment of multiple -hormone-producing malignant islet-cell tumour with streptozotocin. Lancet. 1968; 2: 895-898.
20. Moertel CG, Hanley JA, Johnson LA., Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1980; 303: 1189-1194.
21. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D., Streptozocin- doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992; 326: 519-523.
22. Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol. 2004; 22: 4762-4771.
23. Ramanathan RK, Cnaan A, Hahn RG, Carbone PP, Haller DG., Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol. 2001; 12: 1139-1143.
24. Kulke MH, Stuart K, Enzinger PC, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol. 2006; 24: 401-406.
25. Kulke MH, Stuart K, Earle CC., A Phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. Journal of Clinical Oncology. 2006; 24 (18S): 4044.
26. Fine R, Fogelman D, Schreibman S., Effective Treatment of Neuroendocrine Tumors with Capecitabine and Temozolomide. ASCO Abstract No. 4216. 2005.
27. Murakami J, Lee YJ, Kokeguchi S, et al. Depletion of O6-methylguanine -DNA methyltransferase by O6-benzylguanine enhances 5 -FU cytotoxicity in colon and oral cancer cell lines. Oncol Rep. 2007; 17: 1461-1467.
28. Isacoff WH, Moss RA, Pecora AL, Fine RL., Temozolomide/capecitabine therapy for metastatic neuroendocrine tumors of the pancreas. A retrospective review. Journal of Clinical Oncology. 2006; 24 (18S): 14023.
29. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
30. Kulke MH, Hornick JL, Frauenhoffer C, et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res. 2009; 15: 338-345.